480 results
Keyword Ipilimumab Remove keyword
-
List item
Human medicine European public assessment report (EPAR): Yervoy
Ipilimumab, Melanoma
Date of authorisation: 12/07/2011, Revision: 35, Authorised, Last updated: 18/01/2021ipilimumab … Yervoy, INN-ipilimumab 30 Churchill Place … authorisation) Yervoy ipilimumab On 26 April 2018, the Committee … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Yervoy, Ipilimumab
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Oncology
PIP number: EMEA-000117-PIP02-10-M07, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Concentrate for solution for infusion
Decision date: 12/01/2017, Last updated: 20/03/2017, Compliance check: V, 24/02/2017name Yervoy Active substance Ipilimumab Therapeutic area Oncology … paediatric investigation plan for ipilimumab (Yervoy), (EMEA-000117-PIP02-10-M07 … paediatric investigation plan for ipilimumab (Yervoy), (EMEA-000117-PIP02-10-M07 … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Yervoy, Ipilimumab
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Oncology
PIP number: EMEA-000117-PIP01-07-M07, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Concentrate for solution for infusion
Decision date: 08/05/2015, Last updated: 15/06/2015, Compliance check: V, 11/12/2015name Yervoy Active substance Ipilimumab Therapeutic area Oncology … paediatric investigation plan for ipilimumab (Yervoy), (EMEA-000117-PIP01-07-M07 … paediatric investigation plan for ipilimumab (Yervoy), (EMEA-000117-PIP01-07-M07 … -
List item
Withdrawn application: Yervoy
ipilimumab, date of withdrawal: 30/01/2020, Post-authorisation, Last updated: 23/04/2020Yervoy Yervoy ipilimumab Ipilimumab … -
List item
Human medicine European public assessment report (EPAR): Opdivo
nivolumab, Melanoma, Hodgkin Disease, Carcinoma, Renal Cell, Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Transitional Cell, Urologic Neoplasms
Date of authorisation: 19/06/2015, Revision: 34, Authorised, Last updated: 14/12/2020also be used together with ipilimumab and other cancer medicines … also be used together with ipilimumab and other cancer medicines … back compared Opdivo with ipilimumab. Patients treated with Opdivo … -
List item
Human medicine European public assessment report (EPAR): Keytruda
Pembrolizumab, Melanoma, Hodgkin Disease, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Urologic Neoplasms, Squamous Cell Carcinoma of Head and Neck
Date of authorisation: 17/07/2015,
, Revision: 31, Authorised, Last updated: 28/01/2021
Keytruda or another medicine, ipilimumab. Patients treated with Keytruda … compared with 2.8 months with ipilimumab. Also, up to 74% of patients … compared with 59% of patients on ipilimumab. A third study in 1,019 patients … -
List item
Press release: New treatment option recommended for patients with advanced melanoma
CHMP, Last updated: 22/05/2015other comparing Keytruda with ipilimumab, another melanoma treatment … had not previously received ipilimumab and in patients who had previously … who had previously received ipilimumab. The Committee also looked … -
List item
National expert: Paolo Antonio Ascierto, European Medicines Agency (updated)
- Declaration of interests - 91.63 KB | PDF
- Curriculum Vitae - 71.52 KB | PDF
Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic … Ascierto PA, Pilla L, et al. Ipilimumab and fotemustine in patients … PA. Efficacy and safety of ipilimumab in patients with pre-treated … -
List item
National expert: Piotr Rutkowski, European Medicines Agency (updated)
- Declaration of interests - 85.01 KB | PDF
- Curriculum Vitae - 29.65 KB | PDF
01/2015-(current) BMS nivolumab, ipilimumab melanoma 01/2019-(current … melanoma 05/2013-(current) BMS ipilimumab melanoma 01/2012-(current … 01/2013-(current) BMS nivolumab, ipilimumab, dacarbazine melanoma …